TD2 | Keeping Research on Track | The Power of Noninvasive Optical Imaging in Oncology Drug Development

Preclinical

Optical Imaging - An Efficient Way to Move Drug Programs Forward

CROs can utilize many different methods to evaluate the efficacy of their oncology drug. Optical imaging is a noninvasive method that can provide deeper understanding of efficacy and mechanistic information in more clinically-relevant, orthotopic and disseminated disease models. But how?

Benefits Associated with Noninvasive Optical Imaging

Optical imaging can give rapid insight into efficacy and/or molecular pathway effects. Leveraging a multimodal approach that includes such a powerful tool delivers more meaningful data per study and reduces the amount of preclinical subjects needed to achieve research goals.

Free White Paper:

The Power of Noninvasive Optical Imaging in Oncology Drug Development

An innovative approach to assessments of preclinical efficacy, noninvasive optical imaging is a powerful tool to advance drug programs. Our free white paper shares more about the advantages of noninvasive optical imaging.

Ready to get started?

If you’re seeking a partner who can help set your oncology drug program up for success from the onset, we can help.

Our expert team can help advance your oncology drug development strategy with innovation and efficiency utilizing noninvasive optical imaging. By combining our oncology focus with smart study design, TD2 can accelerate your timeline and provide expert resources and drug development insight every step of the way.

Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered

THE PRECISION ONCOLOGY CRO™

Connect with us on LinkedIn